Friends of Cancer Research’s Post

It’s the best time to work in oncology drug development ! Incredible meeting with the Sarah Cannon Research Institute Early Phase physician investigators at the 27th Annual #SCRI Scientific meeting discussing the length & breath of new drugs in Phase 1 trials #PrecisonOncology #immunotherapy #ADC’s #AI & much much more. #Todaysclinicaltrials = #TomorrowsTherapies OncoAlert OncoDaily

“Every breakthrough in cancer research starts with a clinical trial. At OHC, we see living proof every single day by improving outcomes for our patients,” explains OHC’s David M. Waterhouse, MD, MPH, Director of Early Phase Clinical Trials. He recently attended the Sarah Canon Research Institute’s 27th Annual Scientific Meeting in Nashville with our cancer research and clinical trials program leadership, Zach Beck and Doug Hart. Dr. Waterhouse met with Dr. Vivek Subbiah, Chief of Early Phase Drug Development at SCRI, who stated “Research should be standard of care and standard of care should be research.” Our mission is unwavering, to provide patients with groundbreaking treatments, improve their quality of life, and achieve better outcomes. This starts with research. #cancerresearch #clinicaltrials

Rescuing drugs and the multi-stakeholder approach for drug development - ACCELERATE Multi-Stakeholder Platform #Cancer #ChildhoodCancer #DrugDevelopment #OncoDaily #Oncology

The Food and Drug Administration (FDA) recently released new guidelines for submitting patient-reported outcome (PRO) data collection in cancer clinical trials. The provided link will take you to the Final Guidance Document. Oncology researchers are encouraged to download and review the new guidance and submit comments afterward. https://hubs.ly/Q02dHB1y0 #patientreportedoutcome #PRO #cancerclinicaltrials #oncologyresearch #FDAguidance #foodanddrugadministration #centerfordrugevaluationandresearch #oncologycenterofexcellence

Considerations for Maintenance Therapy in the Community Oncology Setting: Key opinion leaders address the importance of coordination between academic hospital providers and community oncologists when transitioning from initiation of bispecific antibodies at a tertiary hospital to maintenance therapy in the community oncology setting. #finance #pharmacy #lifesciences

In 2023, Oncology Insights covered many hot topics in cancer therapy. With the start of a new year, lets revisit them and highlight a potentially market changing end of the year US Food and Drug Administration (FDA) approval. Read more here: https://bit.ly/48yHqpX

#AUA24 -CHECKMATE901 Phase III trial as first-line therapy for advanced #urothelialcarcinoma #bladdercancer: 1) Nivolumab + GC (Gemcitabine + Cisplatin chemotherapy) showed significant benefits in overall survival (OS), progression-free survival (PFS), and response over GC alone as first-line treatment; 2) Complete remission (CR) rate approximately doubled with Nivolumab+GC to 21.7% with a median duration of CR of 37.1 months; 3) These benefits were attained with a finite duration of chemotherapy (up to 6 cycles) and a maximum of 2 years of nivolumab; 4) Analyses further characterizing patients who responded to treatment are warranted, especially in those who achieved CR (look for update at American Society of Clinical Oncology (ASCO) #ASCO24); 5) In a rapidly evolving treatment landscape, these results provide additional support for Nivolumab + GC as a first-line treatment for patients with advanced urothelial carcinoma- Pleased to present from AdventHealth Central Florida University of Central Florida GU Oncology Now Andrea Necchi Matthew Galsky https://lnkd.in/e9PNi7Ud

The announcement of FDA’s #oncology dose optimization initiative, #ProjectOptimus, is a long-coming step towards improving the dosing of targeted oncology therapies. With this initiative, the #FDA extends guidance on clinical trial design for targeted therapies. While these guidelines should improve patient safety and QOL, the long-term implications for commercializing anticancer drugs are still unfolding. In their latest blog, our colleagues from Health Advances discuss the potential commercial ramifications of Project Optimus and highlight the possible impacts on the targeted therapy pipeline.

💡 Join Syneos Health® for an upcoming webinar to explore insights from oncologists surveyed at the ESMO 2024 conference. #Oncology drug development is advancing rapidly with innovative trials, novel mechanisms of action, and groundbreaking therapies like antibody-drug conjugates (ADCs) and theranostics. 🌟 The featured speakers will highlight the most impactful data from the conference, examining how these cutting-edge treatments are transforming #cancercare. Discover what excites healthcare providers and how the oncology landscape is evolving with personalized medicine and combination therapies. ➡️ Learn more + register here: https://buff.ly/47qHKr6 #DrugDevelopment #ClinicalResearch #OncologyDrugs #OncologyTrials #OncologyClinicalTrials #TherapeuticAreas #OncologyDrugDevelopment #CellAndGeneTherapy

In this on-demand webinar, hear insights from leading cancer drug developers as they discuss key strategies and CMC considerations in managing an orphan drug program and how CDMOs like Catalent could help you bring new treatments to patients faster. https://ow.ly/Rfyy50Qt8YM